Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2025
Business Overview: Bio-Rad is a multinational developer and manufacturer of life science research and clinical diagnostics products. Operations are organized into two segments: Life Science and Clinical Diagnostics. The company serves scientific research, healthcare, education, and government customers globally.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $651.6 | $638.5 | $1,237.0 | $1,249.3 |
| Gross Profit | $345.3 | $355.1 | $651.3 | $681.1 |
| Gross Margin | 53.0% | 55.6% | 52.7% | 54.5% |
| Operating Income | $77.1 | $101.5 | $100.8 | $146.2 |
| Net Income (Loss) | $317.8 | $(2,165.5) | $381.8 | $(1,781.6) |
| Diluted EPS | $11.67 | $(76.26) | $13.84 | $(62.61) |
| Operating Cash Flow (YTD) | $246.4 | $167.4 | $246.4 | $167.4 |
| Total Debt (Long-term + Current) | $1,202.4 | $1,201.6 | $1,202.4 | $1,201.6 |
| Cash & Short-term Investments | $1,373.8 | $1,664.5 | $1,373.8 | $1,664.5 |
Note: Net Income for 2025 includes significant non-operating gains from changes in the fair value of equity securities (Sartorius AG). Prior year losses were driven by significant unrealized losses on the same securities.
Material Changes vs. Prior Period
- Revenue: Q2 2025 net sales increased 2.1% year-over-year (1.0% on a currency-neutral basis). YTD sales decreased 1.0% year-over-year (flat on a currency-neutral basis). Growth was driven by process chromatography products, partially offset by declines in Asia Pacific and lower reimbursements for diabetes testing in China.
- Margins: Consolidated gross margin decreased to 53.0% in Q2 2025 from 55.6% in Q2 2024. The decline was attributed to higher material costs, reduced fixed manufacturing absorption, and restructuring costs.
- Profitability: Operating income decreased 24% in Q2 2025 compared to Q2 2024. However, Net Income swung from a loss of $2.2 billion in Q2 2024 to a profit of $317.8 million in Q2 2025. This reversal is primarily due to a $334.4 million gain from the change in fair market value of equity securities (Sartorius AG) in Q2 2025, compared to a $2.9 billion loss in the same period in 2024.
- Acquisition: On June 30, 2025, the company acquired Stilla Technologies for approximately $257.9 million in net assets (including $161.9 million in goodwill) to strengthen its droplet digital PCR offerings.
- Restructuring: The company incurred $35.6 million in restructuring expenses YTD 2025, primarily related to a new plan approved in February 2025 involving employee terminations and facility consolidations.
Guidance, Outlook, and Risks
- Outlook: Management expects current global economic and geopolitical conditions, including reduced government spending and challenges in the biopharma market, to continue through the rest of 2025. The market in China remains uncertain.
- Capital Allocation: The company repurchased $242.1 million of Class A common stock YTD 2025. As of June 30, 2025, $337.4 million remained available under the 2023 Share Repurchase Program.
- Liquidity: The company maintains $1.4 billion in cash, cash equivalents, and short-term investments. It has a $200 million unsecured Revolving Credit Agreement with no outstanding borrowings as of June 30, 2025.
- Key Risks:
- Investment Volatility: Financial results are materially impacted by the market value of the company's position in Sartorius AG. A decline in this value could result in significant write-downs.
- Geopolitical & Economic: Tariffs, trade barriers, and global economic instability could increase costs and reduce demand.
- Regulatory: Changes in healthcare reimbursement (e.g., Medicare CLFS) and FDA regulations (including potential future regulation of Laboratory Developed Tests) pose risks to the Clinical Diagnostics segment.
- Supply Chain: Disruptions in the supply of components and raw materials could affect manufacturing and sales.
Investor Verification Checklist
- Non-Operating Income Quality: Verify the sustainability of net income by excluding the $334.4 million (Q2) / $366.2 million (YTD) gain from the fair value change of Sartorius AG equity securities.
- Segment Performance: Review the divergence between the Life Science segment (flat to slightly up) and Clinical Diagnostics segment (down due to China reimbursement issues).
- Restructuring Impact: Assess the long-term cost savings versus the immediate $35.6 million expense incurred from the February 2025 restructuring plan.
- Acquisition Integration: Monitor the integration of Stilla Technologies and the realization of synergies in the droplet digital PCR market.
- Debt Covenants: Confirm compliance with leverage ratios given the $1.2 billion outstanding long-term debt and potential future interest rate fluctuations.